Eriksson, M. I.
Syreeni, A.
Sandholm, N.
Dahlström, E. H.
Gordin, D.
Tatlisumak, T.
Putaala, J.
Groop, Per-Henrik http://orcid.org/0000-0003-4055-6954
Martola, J.
Thorn, L. M.
,
Funding for this research was provided by:
Folkhälsanin Tutkimussäätiö
Academy of Finland (275614, 316664, UAK10121MRI)
Wilhelm och Else Stockmanns Stiftelse
Medicinska Understödsföreningen Liv och Hälsa
Novo Nordisk Fonden (NNF OC0013659)
Sigrid Juséliuksen Säätiö
Finska Läkaresällskapet
Otto A. Malm Lahjoitusrahasto
Biomedicum Helsinki-säätiö
Päivikki ja Sakari Sohlbergin Säätiö
Sydäntutkimussäätiö
Finnish governmental EVO grant
Helsingin Yliopisto
Diabetestutkimussäätiö
Diabetes Wellness Suomi Säätiö
Suomen Lääketieteen Säätiö
University of Helsinki including Helsinki University Central Hospital
Article History
Received: 12 December 2022
Accepted: 20 February 2023
First Online: 1 March 2023
Declarations
:
: M.I.E. is a shareholder of BCB Medical Oy. T.T. is an advisory board member of Bayer, Bristol Myers Squibb, Inventiva, and Portola Pharma and has received speaker honoraria from the University of Donau (Austria). D.G. has received lecture or advisory honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Kidney and Liver Foundation in Finland, and Novo Nordisk. J.M. has received lecture honoraria from Santen. P.-H.G. has received lecture honoraria from Astellas, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, PeerVoice, Sanofi and Sciarc, and he is an advisory board member of AbbVie, Astellas, Astra Zeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, Medscape, MSD, Mundipharma, Nestlé, Novartis, Novo Nordisk, and Sanofi. The other authors declare no disclosure.
: All participants gave their written informed consent before inclusion in the study.
: This study was conducted in accordance with the Helsinki Declaration and approved by the Ethics Committee of Helsinki and Uusimaa Hospital District.